PharmaField reported AstraZeneca’s DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) has impacted diabetes standard of care as recently evidenced by the American Diabetes Association (ADA) issuing critical updates to the Standard of Care. The updates went to three sections to incorporate data relating to the AstraZeneca study results.  DECLARE-TIMI 58 was purported to be the largest and longest SGLT-2 inhibitor CVO studied across a wide range of type 2 diabetes patients—it ws the first to include composite hHf or CV death as a primary endpoint. Nearly 60% of patients faced “multiple CV risk factors making it the largest primary prevention population of the SGLT-2i CVOTs.”

Patients struggling with type 2 diabetes face 2X-5X risk of heart failure in addition to risks of other cardiovascular complications such as stroke or heart attack. Additionally, diabetes is the leading cause of chronic kidney disease.


Pin It on Pinterest